12 reports

These include DNA cloning for sequencing, DNA based phylogeny, or functional analysis of genes; the diagnosis of hereditary diseases, the identification of genetic fingerprints (used in forensic sciences and paternity testing); and the detection and diagnosis of infectious

  • Ovarian Cancer
  • bioMerieux S.A.
  • Cepheid
  • Hologic, Inc.
  • Myriad Genetics, Inc.

ARIEL## is a single-arm, open-label, Phase II study designed to identify tumor characteristics that predict sensitivity to rucaparib using DNA sequencing to evaluate each patient' s tumor.

  • Hospital
  • Oncology
  • Ovarian Cancer
  • Therapy
  • AstraZeneca PLC

ARIEL## is a single-arm, open-label, Phase II study designed to identify tumor characteristics that predict sensitivity to rucaparib using DNA sequencing to evaluate each patient' s tumor.

  • Breast Cancer
  • Hospital
  • Ovarian Cancer
  • Therapy
  • AstraZeneca PLC

PARP-## AND PARP-##, WHICH ARE BOTH NUCLEAR ENZYMES, ARE ACTIVATED BY DNA DAMAGE.

  • Oncology
  • Ovarian Cancer
  • Targeted Therapy
  • Therapy
  • AstraZeneca PLC
  • POLYPEPI 1211 CDX - PRODUCT DESCRIPTION

Patient-centred testing We used new DNA sequencing technology to make a fast, accurate, affordable cancer gene test, which is now used across the UK.

  • Clinical Trial
  • Medical Biotechnology
  • Ovarian Cancer
  • United States
  • Pfizer Inc.

ARIEL## is a single-arm, open-label, Phase II study designed to identify tumor Phase III - Trial Details CHARACTERISTICS THAT PREDICT SENSITIVITY TO RUCAPARIB USING DNA SEQUENCING TO EVALUATE EACH PATIENT' S TUMOR.

  • Cancer
  • Ovarian Cancer
  • United States
  • Product Initiative
  • AstraZeneca PLC

PARP-## AND PARP-##, WHICH ARE BOTH NUCLEAR ENZYMES, ARE ACTIVATED BY DNA DAMAGE.

  • Hospital
  • Ovarian Cancer
  • Therapy
  • United States
  • AstraZeneca PLC

ARIEL## is a single-arm, open-label, Phase II study designed to identify tumor characteristics that predict sensitivity to rucaparib using DNA sequencing to evaluate each patient' s tumor.

  • Cancer
  • Ovarian Cancer
  • United States
  • Product Initiative
  • AstraZeneca PLC

RNA and DNA were extracted from ## and ## baseline tumors and analyzed using next generation sequencing (RNA-seq) and Infinium Human Methylation## (HM##) arrays, respectively.

  • Cancer
  • Ovarian Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.
  • VELIPARIB - DRUG PROFILE
  • Other Developmental Activities

PARP-## is a zinc-finger DNA-binding enzyme that is activated by binding to DNA breaks.

  • Oncology
  • Ovarian Cancer
  • United States
  • Company
  • AstraZeneca PLC
  • Phase I - Trial Details

RNA and DNA were extracted from ## and ## baseline tumors and analyzed using next generation sequencing (RNA-seq) and Infinium Human Methylation## (HM##) arrays, respectively.

  • Hospital
  • Immunotherapy
  • Ovarian Cancer
  • Therapy
  • Merck & Co., Inc.

URACIL DNA N-GLYCOSYLASE (UNG) THYMINE DNA GLYCOSYLASE (TDG) URACIL DNA GLYCOSYLASE ## (UNG##) SINGLE-STRAND-SELECTIVE MONO-FUNCTIONAL URACIL-DNA GLYCOSYLASE ## (SMUG ##) METHYL-CPG-BINDING DOMAIN ## (MBD##) METHYL PURINE DNA GLYCOSYLASE (MPG)

  • Oncology
  • Ovarian Cancer
  • North America
  • United States
  • Company